Innovation and corporate governance go hand in hand

Innovation and corporate governance go hand in hand 19 years ago, Yan Xijun, chairman of Shili group, with a paper of approval, a team of dozens of people, less than 10 million yuan and a good idea, founded Tianshi He may not have thought that today, 19 years later, Tianshi has grown into a leading enterprise in the modernization and internationalization of Chinese traditional medicine Yan Xijun said frankly that from the beginning of the company's establishment to the present scale of tens of billions, it's not easy "If an enterprise wants to continue to develop, it must always put innovation first Only through technological innovation, through the organic linkage and promotion of the capital market, coupled with standardized corporate governance, can this enterprise always be competitive." Innovation - the driving force of the enterprise Tianshili Pharmaceutical Group Co., Ltd was founded in 1994 and listed on the Shanghai Stock Exchange on August 23, 2002 with the stock code of 600535 As the leader of the domestic pharmaceutical industry, it has 14 varieties, such as compound Danshen dropping pills, Yangxue Qingnao Granules, and has the industrial platform of modern Chinese medicine, characteristic chemical medicine and biological medicine It is the largest drop pill production enterprise in China at present There is no doubt that innovation and open thinking is an important driving force to promote the rapid growth of Tianshili The company puts forward the cooperation principles of "building a research institute without walls" and "not seeking the place, but seeking the use, achievement ownership and benefit sharing"; it puts forward the employment concept and "talent incentive mechanism" system of "making the compound talents of knowledge economy become the main body of enterprise innovation", which attracts a large number of domestic and foreign talents to join Tianshili It has opened up a new mode of research and development of modern Chinese medicine, established the engineering technology center of component Chinese medicine, and established the component library of Chinese medicine At the same time, Tianshili also actively promotes the internationalization process of traditional Chinese medicine The company's product compound Danshen dropping pill has successfully passed the phase II clinical trial of the U.S Food and Drug Administration (FDA), becoming the first Chinese patent medicine to enter the phase III clinical trial of FDA in China The "going out" of modern traditional Chinese medicine has achieved a historic leap According to the cGMP standard of FDA, the enterprise's technological transformation project has realized the advanced manufacturing of modern Chinese medicine that meets the international standard, and has been highly praised by FDA experts We have signed a clinical trial research cooperation contract with icon and parexel, a US listed company, to ensure the successful completion of phase II clinical trial of global fdaiii of Compound Danshen dropping pills The company's follow-up products silibinin capsule (Shuilinjia) and andrographolide drop pills have also completed the submission of fda-ind Corporate Governance - in an interview, Yan Xijun, the company's escort, thought that when the company grows to a certain scale, how to govern has become a problem that must be faced for continued development To this end, the company strictly follows the requirements of laws and regulations such as the securities law and the governance standards of listed companies, and constantly improves the corporate governance system with the board of directors as the core Through effective internal control management, the company operates in accordance with the law, compliance and efficiency, and actively performs social responsibilities; and gradually strengthens the work functions of the professional committees under the board of directors, Give full play to the role of the board of directors and professional committees in the strategic decision-making and standardized operation of the company to ensure the sustainable and stable development of the company Tianshili's corporate governance and investor relationship management have also been highly recognized by the regulatory authorities As the only pharmaceutical listed company, the company ranked among the top ten corporate governance companies of 915 listed companies in Shanghai Stock Exchange, and won the "2011 board of directors Award" of Shanghai Stock Exchange, and became the only one of 915 companies in Shanghai Stock Exchange to enter the top 20 "board of directors Award" for three consecutive years In 2012, with the company's perfect information disclosure system, strict compliance with information disclosure performance procedures and effective information quick response mechanism, it won the "2012 information disclosure Award" of Shanghai Stock Exchange TSL's board of directors has always attached great importance to the investor relationship management of listed companies and effectively protected the rights and interests of investors After listing in 2002, the company further extended this concept to the investors, the customers of the company's capital market, and always regarded the investor relationship management as a strategic activity for the listed company to transmit the company's information to the relevant stakeholders and pursue the maximization of the relative value of shareholders Internal control -- preventing the risk of enterprise development For a long time, Tianshili has been actively promoting internal control risk management Under the management concept of integrating resources, integrating culture, sorting out processes and eliminating isolated islands, it has implemented the full closed-loop management of process reengineering and economic operation for each business process, and increased enterprise benefits through management innovation, budget control, implementation of organization optimization, process optimization and dynamic cost control The management of the company attaches great importance to the development of internal control Since the promulgation of the guidelines for internal control of the company, a risk control management department has been specially set up to supervise and inspect the management of internal control of each company in the holding system of the pharmaceutical group, to be responsible for the upgrading and improvement of the company's internal control manual, and to carry out the economic operation of the company through the formulation of various risk systems and the establishment of risk indicators All risks in the camp should be indicated and prevented in advance At present, Tianshili has established a relatively perfect internal control system The business operation of each link of the industrial chain is to set standards and authorities one by one, and each business department has fully participated in the internal control system Under the guidance of the spirit of "integrating resources, integrating culture, sorting out processes and eliminating isolated islands", the company's internal control system will continue to improve and gradually improve, and establish an internal control and risk management system that is easy to operate, effective, improved management and compatible with the times With the continuous upgrading of industrial structure and product structure, the marketing mode and scientific research connotation of Tishi power have been further innovated, and technology management and production management have been further expanded An integrated modern industry chain of traditional Chinese medicine has been established to meet a series of standards, from the cultivation of traditional Chinese medicine, intermediate extraction, preparation production to market operation, so as to ensure product quality in all links In strict accordance with the strategic deployment of the board of directors, the management has completed the business indicators over the years and achieved steady growth in performance In the future, the company will also actively integrate into the adjustment of national industrial structure and combine growth with economic and social benefits The company will continue to increase its innovation capacity, build a large platform that can improve the development speed of the enterprise, promote the development of the industry, integrate into the internationalization, continue to expand the industrial pattern of "one core with two wings", and strive to innovate and forge ahead to achieve the goal of "creating health and everyone sharing" Return - the responsibility of the company, Tianshili, has not forgotten to return the support of its shareholders while achieving rapid growth and remarkable performance According to the data, on August 23, 2012, the company was listed on the Shanghai Stock Exchange, with the issue price of 14.7 yuan per share On July 25, 2013, the company's share price reached a record high of 50.05 yuan, and the price after the resumption of rights was 320.48 yuan, 21.80 times of the original issue price Since the company's listing, it adheres to a stable cash dividend return to investors every year, and the annual dividend payout is close to or no less than the level of three of ten At present, it has accumulated a dividend of 1.748 billion yuan The company's initial public offering in 2002 and directional additional offering in 2007 and 2010 raised a total of 2.091 billion yuan in three times At the same time, Tianshili has always been committed to providing employees at all levels with a wide range of development opportunities, a positive innovation environment, a fair incentive mechanism, and constantly committed to making employees create the best value for consumers in a happy working atmosphere Through the combination of "authorization and actual combat" talent training mode to realize the formation of Pharmaceutical Group talent supply chain; through project-based, tutorial system, training system, performance management guidance, Speed up the operation of talent training engine, establish a long-term mechanism of talent inventory and medium and long-term scanning mechanism; through the linkage of theme activities such as "comprehensive skills training camp in charge", "technical competition", "internal post certification" and "technical tutor system", improve the comprehensive quality of employees, increase the cohesion of enterprises, and promote the harmonious development of employees and enterprises In 2012, the company was selected as the 2012 China enterprise training demonstration base by the top 100 Organizing Committee of China enterprise education Yan Xijun, chairman of the board of directors, said that with the help of the capital market, we will further consolidate the industrial foundation and market network, do specialized high-core technology, grow bigger and stronger at a faster speed, and make greater contributions to the country and society Yan Xijun, chairman of Tianshili, won the 2013 China Life Science Entrepreneur Award On November 15, 2013, "Ernst & Young Entrepreneur Award 2013 China" held an award ceremony in Hong Kong 14 Chinese entrepreneurs from all walks of life won awards to commend their positive impact on economic and social development through innovation Yan Xijun, chairman of Tianshili Pharmaceutical Group Co., Ltd., was awarded the 2013 China Life Science Entrepreneur Award of ey Entrepreneur Award It is understood that the ey Entrepreneur Award is one of the most prestigious international business awards in the world This globally recognized award recognizes outstanding entrepreneurs who inspire others with extraordinary vision, leadership and achievements The Ernst & Young Entrepreneur Award was first held in the United States in 1986 It has now been extended to more than 50 countries and 140 cities Over the years, hundreds of the most successful and innovative outstanding entrepreneurs in the world have won the award Previous winners include Michael Dell, founder of Dell computer, and Howard Schulz, chairman of Starbucks The Ernst & Young Entrepreneur Award was first held in China in 2006 and has become a widely recognized award in China Past winners in Hong Kong and Mainland China include Liu Yonghao, chairman of new hope group, Cao Dewang, chairman of Fuyao Glass (600660, stock bar), Li Shufu, chairman of Zhejiang Geely Holding Group, Ma Weihua, former president of China Merchants Bank, etc Cai Weirong, CO chairman of 2013 China project of Ernst & Young Entrepreneur Award, said that "high quality innovation, responsible society" is the theme of this year, and also summarizes the characteristics of these entrepreneurs They are at the forefront of economic transformation, and effectively respond to the multiple challenges of global economic slowdown At the same time, they also combine social benefits with enterprise economic benefits to solve social problems in an innovative way Enterprises bring new business opportunities Yan Xijun, one of the winners, said in an interview that the ey Entrepreneur Award has built a bridge for Chinese enterprises to go to the world and an international evaluation system for Chinese enterprises in the process of development, growth and innovation "Entrepreneurship is to create more products through technological innovation, create more social wealth while expanding the value of enterprises, especially in how to provide employment opportunities for the social vulnerable groups through the innovation of business model, truly reflecting that the wealth of enterprises comes from society, develops in society and returns to society." After 19 years of abandoning the army and starting business, Yan Xi military established a high-tech pharmaceutical enterprise group with the enterprise philosophy of "pursuing the unity of nature and man and improving the quality of life", and the enterprise vision of "creating health and sharing by all" Tianshili created